Jay Cutler TRT: Public Transformation Timeline and Clinical Context

What Jay Cutler Has Said Publicly About TRT

Jay Cutler has been one of the most transparent professional bodybuilders about his post-retirement hormone use. Starting around 2018 and continuing through at least 2024, he has confirmed on podcasts, YouTube interviews, and Instagram that he uses TRT as part of his ongoing health maintenance. He has framed this use as medically supervised and distinct from the supraphysiologic doses used during his competitive career.

2018 to 2020: First Public Acknowledgments

In interviews from this period, Cutler began distinguishing between "being on" as a competitor, meaning supraphysiologic anabolic steroid cycles, and "being on TRT," which he described as keeping testosterone at a physiologically normal level. He told interviewers that retirement had brought significant energy drops, changes in body composition, and mood shifts, symptoms consistent with the clinical picture of hypogonadism. He attributed these changes partly to the hormonal suppression that follows years of exogenous androgen use.

This is not unusual. Research published in the Journal of Clinical Endocrinology and Metabolism found that prolonged anabolic-androgenic steroid (AAS) use suppresses the hypothalamic-pituitary-gonadal (HPG) axis, and axis recovery can take years or may be permanent in some users [1]. A 2019 cross-sectional study (N=132 former AAS users) found that 42% still showed subnormal luteinizing hormone (LH) and testosterone levels more than two years after cessation [2].

2021 to 2023: More Specific Disclosures

By 2021, Cutler was more specific. On the Muscle and Fitness podcast and in a widely circulated YouTube interview, he stated that he works with a physician and has bloodwork done regularly. He described using testosterone in a dose range he characterized as "replacement," not "enhancement." He also mentioned monitoring hematocrit and prostate markers, language consistent with standard TRT safety protocols recommended by both the Endocrine Society and the American Urological Association [3][4].

He noted that his physique had shifted substantially from his competition-era look, with lower overall muscle mass and reduced body weight, which he attributed to the difference between supraphysiologic hormone levels and true replacement-range dosing. Publicly available photos from this period support that observation.

2024: Ongoing Transparency

In multiple 2024 social media posts and podcast appearances, Cutler continued to speak positively about TRT as a quality-of-life measure. He has encouraged fans to get bloodwork done and consult physicians rather than self-medicating. His public framing aligns with a harm-reduction, physician-supervised model rather than the unsupervised self-administration that remains common in recreational bodybuilding circles.

The Clinical Background: Why Former Bodybuilders Often Need TRT

Understanding Cutler's situation requires a brief look at what decades of supraphysiologic androgen use does to the HPG axis, and why replacement therapy often becomes medically necessary.

HPG Axis Suppression and Recovery

The HPG axis is the signaling chain: the hypothalamus releases gonadotropin-releasing hormone (GnRH), which prompts the pituitary to release LH and follicle-stimulating hormone (FSH), which in turn stimulate the testes to produce testosterone. Exogenous androgens suppress GnRH and LH through negative feedback, causing testicular atrophy and reduced endogenous testosterone synthesis [5].

After AAS cessation, the axis may recover partially or fully, or it may not recover at all. A 2020 study in the European Journal of Endocrinology (N=97 former AAS users, median 2.5 years post-cessation) found that 27% still had serum testosterone levels below 300 ng/dL, meeting the biochemical threshold for hypogonadism per most U.S. Guidelines [6].

Diagnosing Hypogonadism: What the Numbers Mean

The Endocrine Society 2018 guideline defines biochemical hypogonadism as a morning total testosterone below 300 ng/dL on two separate measurements, combined with signs and symptoms such as fatigue, decreased libido, reduced muscle mass, or mood disturbance [3]. The FDA has approved testosterone replacement specifically for men with documented hypogonadism, not for age-related decline alone [7].

Free testosterone and sex hormone-binding globulin (SHBG) levels add diagnostic nuance. Men with high SHBG may have normal total testosterone but low free testosterone, the biologically active fraction. Standard TRT protocols aim to bring total testosterone to the mid-normal range, roughly 400 to 700 ng/dL, without exceeding the upper limit of normal [3].

Why Former Elite Athletes Are a Distinct Population

Former competitive bodybuilders often present with a different clinical profile than the typical hypogonadal patient. They may have used very high androgen doses for many years, suppressing the HPG axis more profoundly and for longer. They also often have higher baseline muscle mass, which means the subjective experience of hypogonadism, particularly the loss of strength and body composition, is more noticeable than it might be in a sedentary man.

A 2021 narrative review in Frontiers in Endocrinology noted that former AAS users seeking TRT require longer monitoring periods and more frequent laboratory assessment than first-time TRT patients, given the higher likelihood of erythrocytosis and residual axis suppression [8].

Standard TRT Protocols: What the Guidelines Actually Say

The Endocrine Society guideline recommends testosterone therapy for men with symptomatic hypogonadism, with the goal of restoring testosterone to the mid-normal range. Treatment options include intramuscular or subcutaneous testosterone cypionate or enanthate (typically 50 to 100 mg per week, or 100 to 200 mg every two weeks), transdermal gels, subcutaneous pellets, and nasal gel [3].

Injectable Testosterone

Testosterone cypionate and testosterone enanthate remain the most commonly prescribed forms in the United States. A 2017 systematic review in Cochrane Database (N=3,016 across 58 trials) found that injectable formulations produced more consistent serum testosterone levels compared to transdermal preparations when dosed weekly rather than biweekly [9]. Weekly dosing flattens the peak-and-trough curve that biweekly dosing produces, which many clinicians prefer to minimize side effects and mood variability.

Transdermal Options

Testosterone gels (brand names include AndroGel and Testim) and patches produce steadier daily levels but carry transfer risk to partners and children. The FDA label for AndroGel 1.62% (NDA 022504) specifies application to upper arms or shoulders and warns against skin-to-skin contact until the application site is dry [10].

Monitoring on TRT

Both the Endocrine Society and the American Urological Association recommend checking serum testosterone, hematocrit, PSA, and lipid panels at 3 to 6 months after initiation, then annually once stable [3][4]. Hematocrit above 54% requires dose reduction or temporary discontinuation due to elevated thrombosis risk [3]. Absolute contraindications include active prostate cancer, breast cancer, and desire for near-term fertility, since TRT suppresses spermatogenesis [11].

The Evidence for TRT Benefits in Hypogonadal Men

The clinical benefits of TRT in men with confirmed hypogonadism are well-documented. The Testosterone Trials (TTrials), a coordinated set of seven double-blind, placebo-controlled trials in men 65 and older with low testosterone (N=788), found statistically significant improvements in sexual function, physical function, and bone density at 12 months with testosterone gel vs. Placebo [12].

Body Composition

The TTrials Physical Function Trial found that men receiving testosterone gained a mean of 1.6 kg lean mass vs. A loss of 0.4 kg in the placebo group at 12 months (P<0.001) [12]. Cutler's own public comments about maintaining a leaner, lighter physique on TRT are consistent with what replacement-dose testosterone does: it preserves lean mass without the dramatic hypertrophy seen with supraphysiologic doses.

Bone Density

The TTrials Bone Trial showed a statistically significant increase in volumetric bone mineral density at the spine (7.5% increase vs. 0.8% for placebo, P<0.001) in hypogonadal men at 12 months [13]. This is clinically meaningful for former bodybuilders, whose bone density may paradoxically decline after retirement as anabolic support drops sharply.

Sexual Function and Mood

The TTrials Sexual Function Trial found a significant improvement in sexual desire and erectile function scores at 12 months in the testosterone group vs. Placebo [12]. Separate observational data from a 2018 study in the Journal of Clinical Endocrinology and Metabolism (N=423) found that men with treated hypogonadism reported lower rates of depressive symptoms compared to untreated hypogonadal controls at 24 months [14].

Cardiovascular Considerations: What the Data Now Show

TRT and cardiovascular risk was a major area of controversy after a 2010 trial (Basaria et al., NEJM, N=209) was stopped early due to higher cardiovascular event rates in the testosterone arm [15]. That trial enrolled a high-risk population of older men with mobility limitations, and its findings were not generalizable to younger, healthier hypogonadal men. Subsequent data have been more reassuring.

The TRAVERSE Trial

The TRAVERSE trial (N=5,246, mean age 63.5 years, followed for a mean of 33 months) was a prospective, double-blind, placebo-controlled cardiovascular safety trial of testosterone gel in men with hypogonadism and pre-existing or high risk of cardiovascular disease. Results published in NEJM in 2023 showed that testosterone therapy was non-inferior to placebo for the composite cardiovascular endpoint (major adverse cardiovascular events: 7.0% vs. 7.3%, hazard ratio 0.96, 95% CI 0.78 to 1.17) [16]. The trial did find higher rates of atrial fibrillation, pulmonary embolism, and acute kidney injury in the testosterone arm, outcomes that require clinical attention during monitoring.

Context for Former Bodybuilders

Former AAS users may already carry elevated cardiovascular risk from years of supraphysiologic androgen exposure, including left ventricular hypertrophy and altered lipid profiles [17]. A 2017 study in Circulation (N=140 male strength athletes) found that current and former AAS users had significantly lower left ventricular ejection fraction and higher coronary artery plaque volume compared to non-AAS-using athletes and sedentary controls [17]. This makes cardiovascular baseline assessment, including echocardiography and coronary calcium scoring, reasonable before initiating TRT in former competitive bodybuilders.

What "What Does Jay Cutler Take" Actually Means Clinically

Online searches for "what does Jay Cutler take" reflect broad public curiosity about celebrity supplement and hormone use. Cutler has not published a specific protocol publicly. He has referenced physician oversight, regular bloodwork, and testosterone use. He has also spoken about growth hormone peptides in interviews, though his statements on those are less specific and less consistent.

The table below outlines a clinically reasonable TRT evaluation framework for former competitive bodybuilders, based on current Endocrine Society and AUA guidance, that any physician evaluating a patient with a similar history might use. This is HealthRX's original synthesis for this population.

| Assessment Step | What to Measure | Guideline Source | |---|---|---| | Baseline hormones | Total T (x2, AM), free T, LH, FSH, SHBG, prolactin | Endocrine Society 2018 [3] | | Hematologic | CBC, hematocrit | Endocrine Society 2018 [3] | | Metabolic | Lipid panel, fasting glucose, liver enzymes | AUA 2022 [4] | | Prostate | PSA, DRE if age >40 | AUA 2022 [4] | | Cardiovascular | Resting EKG, BP; consider echo and coronary calcium in former AAS users | Circulation 2017 [17] | | Follow-up | Repeat T, hematocrit, PSA at 3 months, then 6 months, then annually | Endocrine Society 2018 [3] |

Inference vs. Confirmed Information: A Clear Distinction

Journalistic rigor requires being explicit about what Cutler has confirmed vs. What is inferred.

Confirmed (from public statements): Cutler uses TRT under physician supervision. He monitors bloodwork regularly. He distinguishes his current hormone use from competitive-era polypharmacy. He advocates for physician consultation rather than self-medication.

Inferred, not confirmed: The specific form of testosterone (cypionate, enanthate, gel, or pellet), the exact dose, the frequency of administration, and the identity of his prescribing physician are not public information. Any source claiming to know his exact protocol is speculating.

Not supported: There is no credible public evidence that Cutler currently uses supraphysiologic anabolic steroids. His physique, as visible in post-2015 public appearances, is consistent with natural or TRT-level muscle mass for a man in his late 40s and early 50s with his training history.

Access to TRT: The Telehealth Pathway

Men who suspect hypogonadism now have more access to evaluation than at any prior point. Telehealth platforms, including HealthRX, allow patients to order a testosterone panel, complete a symptom assessment, and consult with a licensed physician within days. The FDA requires a valid physician-patient relationship and a confirmed diagnosis before prescribing testosterone, a requirement that reputable telehealth providers follow [7].

The American Association of Clinical Endocrinologists (AACE) published a 2022 position statement emphasizing that TRT should be reserved for men with both biochemical and symptomatic hypogonadism, not prescribed based on symptoms alone or for anti-aging purposes without a confirmed low testosterone level [18].

The Endocrine Society guideline states directly: "We suggest against making a diagnosis of androgen deficiency in men with acute or subacute illnesses, and we recommend measuring serum testosterone level in the morning." [3]